Emerging Insights into Melatonergic Modulation of Epileptogenesis and Seizure Control: An Updated Review

Epilepsy affects approximately 50 million individuals globally, with nearly 30% exhibiting refractory symptoms despite advances in antiseizure medications. There is an urgent need for adjunctive therapies that target underlying pathophysiological mechanisms such as oxidative stress and neuronal hyperexcitability. This review evaluates melatonin’s therapeutic potential in epilepsy management by synthesizing evidence from preclinical models, clinical trials, and mechanistic studies. Melatonin demonstrates pleiotropic anticonvulsant properties mediated through MT1/MT2 receptor-dependent and independent pathways. Key mechanisms include potent antioxidant activity via ROS scavenging, glutathione homeostasis, and Nrf2 pathway activation. It also exerts anti-inflammatory effects by suppressing NF-κB and modulating microglial polarization, while restoring excitatory-inhibitory balance through enhanced GABAergic transmission and inhibition of glutamatergic excitotoxicity. Additional molecular targets include CREB phosphorylation, BDNF expression, and ROR-mediated regulation of circadian genes. Melatonin further preserves mitochondrial integrity and synchronizes circadian rhythms frequently disrupted in epileptogenesis. Preclinical studies consistently report reduced seizure severity and frequency across models including PTZ and kainic acid-induced epilepsy. Human clinical trials, though heterogeneous, indicate that adjunctive melatonin significantly ameliorates seizure severity and sleep disturbances in adults, with a favorable safety profile. Effects on seizure frequency remain inconsistent, particularly in pediatric cohorts with infantile spasms; meta-analytic data support improvements in severity and sleep latency without increased adverse events. In conclusion, melatonin represents a promising, safe, and accessible adjunctive therapy for epilepsy, especially for mitigating seizure severity and comorbid sleep disorders. Future research should prioritize large-scale multicenter randomized controlled trials to establish standardized dosing protocols, optimize administration timing, and identify patient subgroups most likely to benefit

Authors

Institutions

Publication Details

Journal
Advances in Pharmacology and Therapeutics Journal
Published
2026-11-17
DOI
https://doi.org/10.18502/aptj.v6i2.23223
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Emerging Insights into Melatonergic Modulation of Epileptogenesis and Seizure Control: An Updated Review

Mahdi Mashhadi Akbar Boojar
1 links
Advances in Pharmacology and Therapeutics Journal
Epilepsy research and treatment
article

Emerging Insights into Melatonergic Modulation of Epileptogenesis and Seizure Control: An Updated Review

Mahdi Mashhadi Akbar Boojar
article en

Abstract

Epilepsy affects approximately 50 million individuals globally, with nearly 30% exhibiting refractory symptoms despite advances in antiseizure medications. There is an urgent need for adjunctive therapies that target underlying pathophysiological mechanisms such as oxidative stress and neuronal hyperexcitability. This review evaluates melatonin’s therapeutic potential in epilepsy management by synthesizing evidence from preclinical models, clinical trials, and mechanistic studies. Melatonin demonstrates pleiotropic anticonvulsant properties mediated through MT1/MT2 receptor-dependent and independent pathways. Key mechanisms include potent antioxidant activity via ROS scavenging, glutathione homeostasis, and Nrf2 pathway activation. It also exerts anti-inflammatory effects by suppressing NF-κB and modulating microglial polarization, while restoring excitatory-inhibitory balance through enhanced GABAergic transmission and inhibition of glutamatergic excitotoxicity. Additional molecular targets include CREB phosphorylation, BDNF expression, and ROR-mediated regulation of circadian genes. Melatonin further preserves mitochondrial integrity and synchronizes circadian rhythms frequently disrupted in epileptogenesis. Preclinical studies consistently report reduced seizure severity and frequency across models including PTZ and kainic acid-induced epilepsy. Human clinical trials, though heterogeneous, indicate that adjunctive melatonin significantly ameliorates seizure severity and sleep disturbances in adults, with a favorable safety profile. Effects on seizure frequency remain inconsistent, particularly in pediatric cohorts with infantile spasms; meta-analytic data support improvements in severity and sleep latency without increased adverse events. In conclusion, melatonin represents a promising, safe, and accessible adjunctive therapy for epilepsy, especially for mitigating seizure severity and comorbid sleep disorders. Future research should prioritize large-scale multicenter randomized controlled trials to establish standardized dosing protocols, optimize administration timing, and identify patient subgroups most likely to benefit

Advances in Pharmacology and Therapeutics Journal
Baqiyatallah University of Medical Sciences (IR)
Good health and well-being
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon